Detailed description of telisotuzumab-EMRELIS injection method, dosage and patient precautions

Telisotuzumab-EMRELIS is a monoclonal antibody drug targeting the c-Met receptor. It is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) with high expression or amplification of c-Met. c-MetThe receptor is abnormally activated in a variety of tumors and is closely related to tumor cell proliferation, invasion, metastasis and chemotherapy resistance. Terituzumab inhibits tumor growth and enhances the immune system's killing effect on tumors by specifically binding to c-Met receptors, blocking its downstream signaling pathways, and inducing antibody-dependent cellular cytotoxicity (ADCC).

EMRELISThe injection is an intravenous infusion preparation. It needs to be shaken well before use and dissolved at room temperature to ensure uniformity. The recommended method of administration is intravenous infusion, usually slow infusion through a dedicated infusion tube to reduce the risk of infusion-related reactions. The standard dosage and administration period need to be determined according to the patient's weight, body surface area and specific condition. Currently, the commonly used dosage in clinical trials is 2 mg/kg to 3 mg/kg per kilogram of body weight, once every two weeks. During the first medication, the patient's blood pressure, heart rate, body temperature and infusion reaction need to be closely monitored to ensure safety.

In clinical use, terituzumab may cause infusion reactions, including fever, chills, rash, hypotension and respiratory symptoms. To reduce risk, antihistamines, corticosteroids, or antipyretic and analgesics may be administered prophylactically before the first dose. During the treatment process, patients should receive infusions at experienced medical institutions and receive ECG and vital sign monitoring. In addition, the drug may cause liver function abnormalities or hematological changes, so liver enzymes, blood routine and renal function need to be monitored regularly during treatment, and the dose should be adjusted or medication suspended if necessary.

Patient precautions during useEMRELIS also include evaluation of potential drug interactions and lifestyle intervention. Patients should inform their doctors of all medications they are taking, including over-the-counter drugs and supplements, to avoid drug interactions with terituzumab. If serious adverse reactions occur, such as persistent high fever, difficulty breathing, obvious liver function abnormalities or hematological abnormalities, the drug should be discontinued immediately and professional treatment should be carried out. For pregnant women, lactating women, and patients with severe heart, liver, and kidney damage, the risks of medication should be carefully evaluated, and the treatment plan should be delayed or adjusted if necessary.

In general, terituzumab-EMRELIS, as an important drug for c-Met targeted therapy, is c-Met highly expressed in the late stageNSCLCPatients are provided with new treatment options. Its intravenous drip method, safe dosage interval and combined preventive medication measures can minimize infusion reactions and other adverse events. By standardizing injection methods, regularly monitoring clinical indicators and strictly managing medication risks, patients can obtain anti-tumor efficacy while ensuring medication safety, providing reliable support for precise targeted therapy.

Keyword tags: terituzumab, c-Mettargeting, non-small cell lung cancer, injection method, precautions

Reference materials:https://pubmed.ncbi.nlm.nih.gov/?term=telisotuzumab+vedotin